Time filter

Source Type

Barrett A.,Manchester Business Park | Clark M.,RTI Health Solutions | DeMuro C.,RTI Health Solutions | Esser D.,Boehringer Ingelheim GmbH
European Respiratory Journal | Year: 2013

Which proxy-reported outcome measures have been developed for use with children aged 6 years and younger to assess asthma symptoms, asthma control, and asthma-specific health-related quality of life, and do these questionnaires

Hart P.J.,Sheffield Hallam University | Francese S.,Sheffield Hallam University | Claude E.,Manchester Business Park | Woodroofe M.N.,Sheffield Hallam University | Clench M.R.,Sheffield Hallam University
Analytical and Bioanalytical Chemistry | Year: 2011

Lipidomics is a rapidly expanding area of scientific research and there are a number of analytical techniques that are employed to facilitate investigations. One such technique is matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS). Previous MALDI-MS studies involving lipidomic investigation have included the analysis of a number of different ex vivo tissues, most of which were obtained from animal models, with only a few being of human origin. In this study, we describe the use of MALDI-MS, MS/MS and MS imaging methods for analysing lipids within cross-sections of ex vivo human skin. It has been possible to tentatively identify lipid species via accurate mass measurement MALDI-MS and also to confirm the identity of a number of these species via MALDI-MS/MS, in experiments carried out directly on tissue. The main lipid species detected include glycerophospholipids and sphingolipids. MALDI images have been generated at a spatial resolution of 150 and 30 μm, using a MALDI quadrupole time-of-flight Q-Star Pulsar-i TM (Applied Biosystems/MDS Sciex, Concord, ON, Canada) and a MALDI high-definition MS (HDMS) SYNAPT G2-HDMS TM system (Waters, Manchester, UK), respectively. These images show the normal distribution of lipids within human skin, which will provide the basis for assessing alterations in lipid profiles linked to specific skin conditions e.g. sensitisation, in future investigations. © 2011 Springer-Verlag.

Brodtkorb T.-H.,RTI Health Solutions | Bell M.,Manchester Business Park | Irving A.H.,University of Sydney | Laramee P.,Social and Epidemiological Research Program
CNS Drugs | Year: 2016

Aim: To evaluate costs and health outcomes of nalmefene plus psychosocial support, compared with psychosocial intervention alone, for reducing alcohol consumption in alcohol-dependent patients, specifically focusing on societal costs related to productivity losses and crime. Methods: A Markov model was constructed to model costs and health outcomes of the treatments over 5 years. Analyses were conducted for nalmefene's licensed population: adults with both alcohol dependence and high or very high drinking-risk levels (DRLs) who do not require immediate detoxification and who have high or very high DRLs after initial assessment. The main outcome measure was cost per quality-adjusted life-year (QALY) gained as assessed from a UK societal perspective. Alcohol-attributable productivity loss, crime and health events occurring at different levels of alcohol consumption were taken from published risk-relation studies. Health-related and societal costs were drawn from public data and the literature. Data on the treatment effect, as well as baseline characteristics of the modelled population and utilities, came from three pivotal phase 3 trials of nalmefene. Results: Nalmefene plus psychosocial support was dominant compared with psychosocial intervention alone, resulting in QALYs gained and reduced societal costs. Sensitivity analyses showed that this conclusion was robust. Nalmefene plus psychosocial support led to per-patient reduced costs of £3324 and £2483, due to reduced productivity losses and crime events, respectively. Conclusion: Nalmefene is cost effective from a UK societal perspective, resulting in greater QALY gains and lower costs compared with psychosocial support alone. Nalmefene demonstrates considerable public benefits by reducing alcohol-attributable productivity losses and crime events in adults with both alcohol dependence and high or very high DRLs who do not require immediate detoxification and who have high or very high DRLs after initial assessment. © 2016 Springer International Publishing Switzerland.

Curran S.A.,Cardiff Metropolitan University | Hirons R.,Manchester Business Park
Prosthetics and Orthotics International | Year: 2012

In the last 25 years, the continuous evolution in the design of prostheses for individuals with transfemoral and transtibial amputations has been remarkable. Mirroring this development is the dependency and expectancy of the prosthesis technology by the athletes, coaches and other personnel involved in creating Paralympians of today and the future. Össur is recognised as a leader in designing innovative prosthetic products that have contributed worldwide to developing leading Paralympians. The opening section of this article presents an overview of the new Össur products for 2012. Discussion is also focussed on how Össur's high-function prosthetic products are integrated into an athlete's training regime. With involvement of the clinical team discussion is also expanded to recognise the important contribution coaching staff has on optimising performance of a Paralympian's training regime. The dialogue continues with a viewpoint on whether Oscar Pistorius, the face of Össur who wears Flex-Foot Cheetah blades, should participate in the Olympics and Paralympics. While the conclusion of this article may leave more questions than answers, the technology and products offered by Össur provide for a credible foundation and preparation for future challenges beyond the London 2012 Paralympic Games. © 2012 The International Society for Prosthetics and Orthotics.

Crumbleholme T.,Manchester Business Park
IET Seminar Digest | Year: 2015

Presents a collection of slides covering the following: pumps; fault signal; workforce management information; and data quality.

Discover hidden collaborations